Significance of HbA1c test is a stable indicator of triglycerides in diagnosis and prognosis of diabetic patients

J. Sudha Rani


Background: The main purpose of the study was to highlight the relationship between glycosylated hemoglobin (HbA1c) and triglyceride levels in type 2 DM. Insulin resistance is associated with the elevated triglycerides (TG), and persons with type-2 diabetes are insulin resistant However, it is unknown what level of glycemia that causes an increase in TGL. Hence Therefore I am interested to determine the quantitative relationship between the hemoglobin A1C (HbA1c) and TGL.

Methods: This descriptive study was conducted at GVPIHC&MT Marikavalasa, Visakhapatnam-4. The study population included 100 patients (not discriminate Male/ Female) of type 2 DM not on lipid lowering medication and 100 subjects without DM as controls from the department of General Medicine. For statistical analysis, Chi-square and Pearson’s correlation coefficient was used to find the association between triglyceride and HbA1c.

Results: The association of high triglyceride was evaluated in type 2 DM group of HbA1c, with a cut-off value 7% patients had high triglycerides and showed a significant association with high HbA1c levels at p<0.0001.

Conclusions: It has been shown from this study Triacylglycerol level are high with HbA1c (with a cut-off value 7%) level was found higher in diabetic patients when compared with the controls. Therefore, proper glycemic control should be maintained by maintaining HbA1c level less than 6.0% to prevent multifactorial disorder of diabetic complications.


Diabetes Mellitus (DM), Glycated hemoglobin (HbA1c), Triglycerides (TG)

Full Text:



National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose tolerance. Diabetes. 1979;28:1039-57.

Lee J, Son H, Ryu OH. Management status of cardiovascular disease risk factors for dyslipidemia among Korean adults. Yonsei Med J. 2017;58:326-38.

Dake AW, Sora ND. Diabetic dyslipidemia review: an update on current concepts and management guidelines of diabetic dyslipidemia. Am J Med Sci. 2016;351:361-5.

Sarfraz M, Sajid S, Ashraf MA: Prevalence and pattern of dyslipidemia in hyperglycaemic patients and its associated factors among Pakistani population. Saudi J Biol Sci. 2016;23:761-6.

Verges B: Lipid modification in type 2 diabetes: the role of LDL and HDL . Fundam Clin Pharmacol. 2009;23:681-5.

Naseem S, Khattak UK, Ghazanfar H. Prevalence of non-communicable diseases andtheir risk factors at a semi-urban community, Pakistan. Pan Afr Med J. 2016;23:151.

Dyslipidemia in Patients with a Cardiovascular Risk and Disease at the University Teaching Hospital of Yaoundé, Cameroon Moor VJ, Ndongo Amougou S, Ombotto S, et al.: HYPERLINK ""Ama. Int J Vasc Med. 2017;2017:6061306.

Mahalle N, Garg MK, Naik SS. Study of pattern of dyslipidemia and its correlation with cardiovascular risk factors in patients with proven coronary artery disease. Indian J Endocrinol Metab. 2014;18:48-55.

Rahman S, Kumar P, Mahto SK. Light chain myeloma-induced severe hypertriglyceridemia. J Clin Diagn Res. 2017;11:01-3.

Kushner PA, Cobble ME: Hypertriglyceridemia: the importance of identifying patients at risk. Postgrad Med. 2016;128:848-58.

Quispe R, Martin SS, Jones SR. Triglycerides to high-density-lipoprotein-cholesterol ratio,glycemic control and cardiovascular risk in obese patients with type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2016;23:150-6.

Ren Y, Luo X, Wang C. Prevalence of hypertriglyceridemic waist and association withrisk of type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev. 2016;32:405-12.

Chen GY, Li L, Dai F. Prevalence of and risk factors for type 2 diabetes mellitus in hyperlipidemia in China. Med Sci Monit. 2015;21:2476-84.

Roy S, Sherman A, Monari-Sparks MJ. Association of comorbid and metabolic factors with optimal control of type 2 diabetes mellitus. N Am J Med Sci. 2016;8:31-9.

The International Expert Committee, “International expert committee report on the role of the A1C assay in the diagnosis of diabetes,” Diabetes Care. 2009;32(7):1327-34.

Sabanayagam C, Liew G, Tai ES. “Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes?,” Diabetologia. 2009;52(7):1279-89.

Ahmad BAK, Hassan NU, Kaiser RM, Alvi KY. “Frequency of hypertriglyceridemia in newly diagnosed type 2 diabetics,” Pakistan Armed Forces Medical Journal. 2016;66(1).

Chehade JM, Gladysz M, Mooradian AD, “Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management,” Drugs. 2013;73(4);327-39.

Dixit AK, Dey R, Suresh A. “The prevalence of dyslipidemia in patients with diabetes mellitus of Ayurveda Hospital,” J Diabetes Metabolic disorders. 2014;13(1):58,

Bry L, Chen PC, Sacks DB. Effects pf haemoglobin variants and chemically modified derivatives on assays for glycohemoglobin (Review), Clin Chem. 2001;47:153-63.

Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, Fourth Edition. Carl A. Burtis, Edward R. Ashwood, and David E. Bruns, editors.

Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lipids Health Dis. 2014;13:183.

Patel VI, Patel KP, Makadia MG. Levels of apolipoprotein a1, b100 and lipoprotein (a) in controlled and uncontrolled diabetic patients and in non-diabetic healthy people. J Clin Diagn Res. 2017;11:01-5.

Mortensen LS, Hartvigsen ML, Brader LJ. Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein. Am J Clin Nutr. 2009;90:41-8.

Lebovitz HE, Ludvik B, Yaniv I. Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm. Diabetic Med. 2013;30:687-93.

Parhofer KG. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J. 2015;39:353-62.

Hussain A, Ali I, Ijaz M, Rahim A. Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. Ther Adv Endocrinol Metab. 2017;8:51-7.

Valensi P, Avignon A, Sultan A. Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol. 2016;15:104.

Schofield JD, Liu Y, Rao-Balakrishna P. Diabetes dyslipidemia. Diabetes Ther. 2016;7:203-19.

Cohen RM, Franco RS, Khera PK. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood. 2008;112:4284-91.